61 completed, 21 unknown, 17 recruiting, 17 terminated. 138 Phase 3, 32 Phase 2.
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Best Practice, Biospecimen Collection, Cytarabine - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 556 | 2026-08-14 | 2026-09-04 |
| A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Pivekimab Sunirine, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | AbbVie | 660 | 2026-06-30 | 2026-10-22 |
| A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia BL-M11D1, Cytarabine, Daunorubicin - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 216 | 2026-04-02 | 2026-09-10 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) Bleximenib, Cytarabine, Daunorubicin or Idarubicin - Acute Myeloid Leukemia | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 875 | 2026-03-01 | 2026-11-06 |
| Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax Venetoclax, Azacitidine (AZA) - Acute Myeloid Leukemia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 250 | 2026-02-01 | 2026-02-12 |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy Venetoclax 400, Placebo - Acute Myeloid Leukemia | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 227 | 2025-08-05 | 2025-08-19 |
| IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. High intensity therapies, Low intensity therapies - Acute Myeloid Leukemia, Relapse/Recurrence | Phase 3 | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 339 | 2025-02-27 | 2026-10-27 |
| Twice-per-weekSelinexor, 2 Days Melphalan Selinexor, Melphalan, Intravenous Busulfan - Acute Myeloid Leukemia | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 126 | 2024-09-30 | 2024-09-25 |
| A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia APG-2575(Lisaftoclax ), Placebo, Azacitidine Injection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 486 | 2024-06-11 | 2025-11-25 |
| A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia HMPL-306 Regimen, Salvage Chemotherapy Regimen - Acute Myeloid Leukemia | Phase 3 | Recruiting | Hutchmed | 316 | 2024-04-26 | 2025-08-14 |
| VA vs DA for Newly Diagnosed Hig-risk AML Venetoclax Oral Tablet, Daunorubicin - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 116 | 2024-04-01 | 2026-09-02 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis Baricitinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 150 | 2023-12-01 | 2024-08-23 |
| Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients Experimental: Venetoclax in combination with Decitabine (+-sorafenib), Active Comparator: Standard dose of Venetoclax + Azacitidine - Elderly AML Patients, Unfit, New-diagnosis AML | Phase 3 | Completed | The Second Affiliated Hospital of Kunming Medical University | 154 | 2023-11-01 | 2026-09-09 |
| Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies Fludarabine, busulfan and melphalan, Fludarabine and Busulfan - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 222 | 2023-10-19 | 2025-02-18 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML Venetoclax, Homoharringtonine, Cytarabine - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 60 | 2023-03-01 | 2023-04-07 |
| Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia Interferon - Acute Myeloid Leukemia | Phase 3 | Recruiting | Peking University People's Hospital | 96 | 2023-01-01 | 2025-01-31 |
| Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML Azacitidine Combined With Venetoclax and ATRA group - Acute Myeloid Leukemia | Phase 3 | Completed | The First Affiliated Hospital of Soochow University | 60 | 2022-10-31 | 2026-06-18 |
Showing 20 of 138. Sign in to see all of them.
Leukemia, Myeloid, Acute (138) · Myelodysplastic Syndromes (24) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Leukemia (7) · Leukemia, Biphenotypic, Acute (6) · Multiple Myeloma (5) · Graft vs Host Disease (4) · Hematologic Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Myelomonocytic, Chronic (4) · Lymphoma, Non-Hodgkin (4) · Myeloproliferative Disorders (4) · Anemia, Refractory, with Excess of Blasts (3) · Hodgkin Disease (3)
Hemic and Lymphatic Diseases (138) · Neoplasms by Histologic Type (138) · Leukemia, Myeloid (137) · Hematologic Diseases (136) · Neoplasms (136) · Leukemia (131) · Bone Marrow Diseases (26) · Immune System Diseases (19) · Immunoproliferative Disorders (18) · Lymphatic Diseases (18) · Lymphoproliferative Disorders (18) · Leukemia, Lymphoid (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Disease Attributes (13)
Cytarabine (40) · Daunorubicin (21) · Azacitidine (20) · venetoclax (16) · Decitabine (13) · Idarubicin (12) · fludarabine (12) · Cyclophosphamide (10) · Mitoxantrone (9) · Busulfan (8) · Gemtuzumab (8) · Etoposide (7) · Granulocyte Colony-Stimulating Factor (6) · Methotrexate (6) · Stem Cell Transplantation (6)
The First Affiliated Hospital of Soochow University (10) · Nanfang Hospital, Southern Medical University (7) · University of Ulm (7) · Acute Leukemia French Association (5) · Children's Oncology Group (5) · National Cancer Institute (NCI) (4) · Stichting Hemato-Oncologie voor Volwassenen Nederland (4) · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences (3) · AbbVie (2) · Actinium Pharmaceuticals (2) · Assistance Publique - Hôpitaux de Paris (2) · Astex Pharmaceuticals, Inc. (2) · French Innovative Leukemia Organisation (2) · Gilead Sciences (2) · Institute of Hematology & Blood Diseases Hospital, China (2)
United States (47) · France (40) · Germany (39) · China (34) · Spain (30) · Italy (25) · Austria (23) · Canada (23) · Australia (21) · United Kingdom (20) · Belgium (18) · Poland (17) · Hungary (15) · Czechia (13) · South Korea (12)
Qifa Liu (4) · Depei Wu, M.D., Ph.D. (3) · Hartmut Doehner, MD (2) · Patrick Stiff, MD (2) · Richard F Schlenk, Dr. (2) · Xiaowen Tang, Ph.D. (2) · Agha Mounzer, MD (1) · Alberto Bosi, MD (1) · Arnaud Pigneux, MD, PhD (1) · Avinash Desai, MD (1) · B.J. Wouters (1)
PMID 19602710, PMID 20625116, PMID 21343560, PMID 21459791, PMID 22649106, PMID 22965967, PMID 23248249, PMID 23749683, PMID 24816240, PMID 30337300, PMID 36064577, PMID 37703506, PMID 40973764, PMID 16939487, PMID 17252021, PMID 18838471, PMID 19059939, PMID 19443658, PMID 19470696, PMID 20805454, PMID 21459795, PMID 21690555, PMID 22323482, PMID 22730539, PMID 22911473, PMID 22959335, PMID 23071272, PMID 23321257, PMID 23583763, PMID 23863898, PMID 23878140, PMID 23975179, PMID 24366930, PMID 24498872, PMID 24616160, PMID 24659740, PMID 24797300, PMID 24923295, PMID 25270908, PMID 25299584, PMID 25624327, PMID 25987659, PMID 26234174, PMID 26635039, PMID 26735993, PMID 27276561, PMID 27696203, PMID 28419486, PMID 29241450, PMID 29396857
U10CA180886 (4), 2016 (3), 2018 (3), 2014 (2), 2015 (2), 2025 (2), U10CA180888 (2), UG1CA189955 (2), 2005 (1), 2017 (1), 2023 (1), P01CA018029 (1), P30CA015704 (1), R01CA115422 (1), R01CA132946 (1)